Jonathan B Rosenberg, Edward K Fung, Jonathan Dyke, Bishnu P De, Howard Lou, James Kelly, Layla Reejhsinghani, Rodolfo J Ricart Arbona, Dolan Sondhi, Stephen M Kaminsky, Nathalie Cartier, Christian J Hinderer, Juliette Hordeaux, James M Wilson, Douglas Ballon, Ronald G Crystal
Based on studies in experimental animals demonstrating that administration of adeno-associated virus (AAV) vectors to the cerebrospinal fluid (CSF) is an effective route to transfer genes to the nervous system, there are increasing number of clinical trials using the CSF route to treat nervous system disorders. With the knowledge that the CSF turns over 4 to 5 times daily, and evidence in experimental animals that at least some of CSF administered AAV vectors are distributed to systemic organs, we asked: with AAV administration to the CSF, what fraction of the total dose remains in the nervous system and what fraction goes off target and is delivered systemically? To quantify the biodistribution of AAV capsids immediately after administration, we covalently labeled AAV capsids with iodine 124 (I-124), a cyclotron generated positron emitter, enabling quantitative positron tomography (PET) scanning of capsid distribution for up to 96 hours after AAV vector administration...
August 25, 2023: Human Gene Therapy